Biodexa Pharmaceuticals: Funding, Investors & Team (Oct 2026)
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a commercial platform and four marketed products in the US. Midatech's strategy is to develop products in-house in oncology and with partners in other indications, and to accelerate growth organically and through strategic acquisitions.
Biodexa Pharmaceuticals has raised $3.5M across 1 funding round on record, the most recent an undisclosed round of $3.5M announced in Jun 2026.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Biodexa Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Biodexa Pharmaceuticals Funding Rounds
Biodexa Pharmaceuticals Founders and Leadership Team
Contact details for the Biodexa Pharmaceuticals team: 1 of 1 has an email address on file.
Start 14-day free trial →Biodexa Pharmaceuticals Funding Compared to Other Biotechnology Startups
Biodexa Pharmaceuticals' latest round of $3.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Biodexa Pharmaceuticals in Biotechnology and Abingdon
Companies Similar to Biodexa Pharmaceuticals
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Biodexa Pharmaceuticals Funding FAQs
What does Biodexa Pharmaceuticals do?
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a commercial platform and four marketed products in the US. Midatech's strategy is to develop products in-house in oncology and with partners in other indications, and to accelerate growth organically and through strategic acquisitions.
How much funding has Biodexa Pharmaceuticals raised?
Biodexa Pharmaceuticals has raised $3.5M across 1 round on record. The most recent is an undisclosed round of $3.5M announced in Jun 2026.
When did Biodexa Pharmaceuticals last raise funding?
Biodexa Pharmaceuticals' most recent funding round on record is an undisclosed round of $3.5M, announced in Jun 2026.
Who founded Biodexa Pharmaceuticals?
FundedIQ lists Stephen Stamp (Founder) at Biodexa Pharmaceuticals.
Where is Biodexa Pharmaceuticals headquartered?
Biodexa Pharmaceuticals is based in Abingdon, Oxfordshire, United Kingdom.
How many employees does Biodexa Pharmaceuticals have?
Biodexa Pharmaceuticals is in the 11-50 employee band.
How does Biodexa Pharmaceuticals' funding compare to other Biotechnology startups?
Biodexa Pharmaceuticals' latest round of $3.5M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Biodexa Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Biodexa Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.